breast cancer SD Flashcards

1
Q

What is tissue involution?

A

changes in the breast with increasing age

involutional changes are changes due to altered sex steroid levels that accopany decreasing ovarian fxn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sx of breast disease

A

lumpiness

pain

palpable mass

nipple discharge

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

most common type of benign breast tumour

A

fibroadenoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2 types of breast carcinomas

A
  1. non-invasive
    - ductal carcinoma in situ DCIS
    - lobular carcinoma in situ LCIS
  2. invasive/infiltrating carcinoma
    - infiltrating ductal carcinoma
    - invasive lobular carcinoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

tests for metastases

A
  • lymph node ultrasound/biopsy
  • MRI scan
  • CT scan
  • liver ultrasound
  • bone scan
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

stages of BC

A

STAGE 0: DCIS, pre-invasive BC, cancer cells are in breast ducts and have not started to spread into surrounding breast tissue

STAGE 1: cancer is small and only in breast tissue or might be in lymph nodes close to breast, early stage

STAGE 2: cancer is in breast or in nearby lymph nodes or both, early stage

STAGE 3: cancer has spread from breast to lymph nodes close to breast or to skin of breast or chest wall, locally advanced breast cancer

STAGE 4: cancer has spread to other parts of the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How is the ER/PR/HER2 receptor status determined?

A

immunohistochemistry

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What does triple positive BC mean?

A

ER +ve
PR +ve
HER2 +ve

-> no mutations, could be early stage cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which ER type is in breast?

A

ER alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What type of drug is Tamoxifem?

A

SERM

-> doesn’t allow helix H12 to fit correctly, antagonist effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does tamoxifen prevent?

A

prevents ER gene co-activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How does Tamoxifen work?

A
  • binds to ER at helix H12
  • masks the AF2 site
  • leads to less co-activator recruitment
  • partial agonist/antagonist
  • activates other genes - pro-apoptotic genes, dec proliferation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

2 actions of SERMs (tamoxifen and raloxifine)

A
  • estrogenic and antiestrogenic actions depending on target tissue
  • antiestrogenis in mammary tissue
  • proestrogenic on uterine epithelium and bone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How can Tamoxifen resistance occur?

A
  • loss of ER expression in patient
  • activating ER mutations
  • ER is hypersensitised to low oestrogen levels
  • increased oestrogen levels -> competition
  • pharmacologic tolerance, inc efflux OR dec influx of the drug by membrane pump glycoproteins (Tamoxifen pumped out of cell)
  • R crosstalk (HER2)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do aromatase inhibitors work?

A

inhibit aromatase converting androgens to oestrogens

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

examples of reversible aromatase inhibitors

A

aminoglutethimide - poor selectivity

anastrazole, Letrozole - bind to haem group of aromatase and prevents binding to steroid

17
Q

example of irreversible aromatase inhibitors

A

Exemestane

18
Q

Fulvestrant

A
  • new ER antagonist
  • brand = Faslodex
  • SERD - selective ER degrader
  • binds tightly to ER
  • masks both AF1 & AF2 sites
  • causes receptor instability
  • ER is degraded by the proteome
19
Q

difference between Fulvestrant and Tamoxifen

A

masks both AF1 and AF2 sites

doesn’t allow ER into nucleus

20
Q

Tx if patient ER +ve

21
Q

Tx if patient HER2 +ve

22
Q

What can ER crosstalk with?

A

HER2 receptor

23
Q

What family is HER2 from?

A

EGFR family

24
Q

How do the HER activating ligands work?

A

HER 1, 3 and 4 require HER 2

HER 2 binds to HER 1, 3 or 4, dimerises and becomes active

25
normal vs malignant growth with HER2 R
* low HER 2 - weak signalling, normal growth * high HER 2 - potent signalling, malignant growth
26
What type of receptor is HER2?
cell surface tyrosine kinase receptor
27
% of BC that overexpress HER2
20-30%
28
Tx to block HER2
Herceptin - Trastuzumab MAb well tolerated
29
s/e with Herceptin
CV dysfunction
30
monitoring for Herceptin
cardiac fxn
31
What protein does HER2 use to activate proliferation/attract blood vessels?
VEGF
32
HER2 p95 fragment
* HER2 can undergo proteolytic cleavage in overexpressing cells * leads to extracellular domain fragment being shed * leaves active p95 domain * poor prognosis
33
6 MOA of Herceptin
1. blocks cleavage, prevents autophosphorylation 2. blocks dimerisation (of other HER R) 3. endocytosis of HER2 4. activation of antibody dependent cell mediated cytotoxicity: ADCC (immune system attack HER2) 5. blocks VEGF and tumour vascularisation 6. upregulates p27 to block cell cycle
34
How can you get Herceptin resistance?
1. HER2 p95 fragment generation 2. epitope masking by mucin 3. epitope masking by CD44 -> Herceptin can't bind when any of these happen
35
What region does Herceptin bind to on HER2?
region 4
36
drug for Herceptin resistance and MOA
* Pertuzumab * binds to region 2 (not 4 - Herceptin) * overcomes resistance by p95 clevage and masking
37
Where does Pertuzumab bind to on HER2?
region 2
38
When is Pertuzumab licenced to be given?
in combination with docetazel and trastuzumab (Herceptin)
39
Trastuzumab Emtansine -> Kadcyla
* antibody-drug conjugate: - Trastuzumab linked to DM1 (microtubule inhibitor) * effect = prevention of microtubule polymerisation and initiation of apoptosis (by DM1) * licenced for Tx of HER2 +ve, unresectable, locally advanced/metastatic BC * previosuly received trastuzumab + taxane (separate or combination) * should have: - received Tx for locally advanced/metastatic disease OR - developed disease recurrence during/within 6mths of completing adjuvant therapy